万达生物制药(VNDA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

VNDA 万达生物制药

盘前交易 10-05 04:09:18 EDT

4.63

-0.18

-3.74%

盘前4.51

-0.12-2.59%

04:00 EDT

最高4.85	最低4.57	成交量144.90万
今开4.85	昨收4.81	日振幅5.93%
总市值2.80亿	流通市值2.21亿	总股本6,046万
成交额675.12万	换手率3.04%	流通股本4,766万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"VNDA","market":"US","secType":"STK","nameCN":"万达生物制药","latestPrice":4.63,"timestamp":1790971200000,"preClose":4.81,"halted":0,"volume":1448962,"hourTrading":{"tag":"盘前","latestPrice":4.51,"preClose":4.63,"latestTime":"04:00 EDT","volume":845,"amount":3899.2799625000002,"timestamp":1791187220763,"change":-0.12,"changeRate":-0.025918,"amplitude":0},"delay":0,"changeRate":-0.03742203742203737,"floatShares":47660500,"shares":60462687,"eps":-4.629083,"marketStatus":"盘前交易","change":-0.18,"latestTime":"10-05 04:09:18 EDT","open":4.85,"high":4.85,"low":4.565,"amount":6751200.809231999,"amplitude":0.059252,"askPrice":7.4,"askSize":200,"bidPrice":1.99,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-4.629083,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791207000000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1144814400000,"exchange":"NASDAQ","adjPreClose":4.63,"preHourTrading":{"tag":"盘前","latestPrice":4.51,"preClose":4.63,"latestTime":"04:00 EDT","volume":845,"amount":3899.2799625000002,"timestamp":1791187220763,"change":-0.12,"changeRate":-0.025918,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":4.58,"preClose":4.63,"latestTime":"19:47 EDT","volume":21211,"amount":97649.5914,"timestamp":1790984825179,"change":-0.05,"changeRate":-0.010799,"amplitude":0.012462},"volumeRatio":0.8391013168200149,"impliedVol":1.6445,"impliedVolPercentile":0.944},"requestUrl":"/m/hq/s/VNDA","defaultTab":"news","newsList":[{"id":"1159291923","title":"欧洲委员会授予万达生物制药Imsidolimab治疗泛发性脓疱型银屑病的孤儿药资格","url":"https://stock-news.laohu8.com/highlight/detail?id=1159291923","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159291923?lang=zh_cn&edition=full","pubTime":"2026-08-24 19:01","pubTimestamp":1787569269,"startTime":"0","endTime":"0","summary":"欧洲委员会已正式授予万达生物制药（Vanda Pharmaceuticals）旗下在研药物Imsidolimab用于治疗泛发性脓疱型银屑病的孤儿药资格认定。这一决定标志着该药物在罕见皮肤病领域获得了监管层面的重要认可，有望加速其后续的临床开发与上市审批进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VNDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111995389","title":"万达生物制药宣布Imsidolimab治疗GPP获欧洲药品管理局孤儿药资格积极意见","url":"https://stock-news.laohu8.com/highlight/detail?id=1111995389","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111995389?lang=zh_cn&edition=full","pubTime":"2026-07-17 04:31","pubTimestamp":1784233875,"startTime":"0","endTime":"0","summary":"万达生物制药宣布，其候选药物Imsidolimab用于治疗泛发性脓疱型银屑病（GPP）的孤儿药资格申请，已获得欧洲药品管理局（EMA）人用药品委员会（CHMP）的积极意见。\n孤儿药资格旨在鼓励针对罕见疾病的药物开发。获得EMA的积极意见是Imsidolimab在欧洲监管路径上的一个重要进展，为其后续的上市申请奠定了基础。这一进展有望为GPP患者带来新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130581087","title":"万达生物制药Imsidolimab治疗GPP的BLA申请获FDA受理，目标审评日期定于2026年12月12日","url":"https://stock-news.laohu8.com/highlight/detail?id=1130581087","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130581087?lang=zh_cn&edition=full","pubTime":"2026-07-17 04:31","pubTimestamp":1784233873,"startTime":"0","endTime":"0","summary":"万达生物制药（Vanda Pharmaceuticals）用于治疗泛发性脓疱型银屑病（GPP）的候选药物Imsidolimab的生物制品许可申请（BLA），目前正处于美国食品药品监督管理局（FDA）的审评流程中。FDA已为该申请设定了目标审评日期，定为2026年12月12日。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143586895","title":"万达生物制药宣布其夏科-马里-图斯病2S型在研疗法获FDA儿科罕见病资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=1143586895","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143586895?lang=zh_cn&edition=full","pubTime":"2026-07-08 04:31","pubTimestamp":1783456277,"startTime":"0","endTime":"0","summary":"万达生物制药近日宣布，其针对夏科-马里-图斯病2S型（Charcot-Marie-Tooth Disease Type 2S）的在研疗法，已获得美国食品药品监督管理局（FDA）授予的儿科罕见病资格认定。这一认定标志着该疗法在针对这一罕见儿科疾病的研究与开发进程中取得了重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108747012","title":"日本授予Imsidolimab孤儿药资格，用于治疗泛发性脓疱型银屑病","url":"https://stock-news.laohu8.com/highlight/detail?id=1108747012","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108747012?lang=zh_cn&edition=full","pubTime":"2026-05-27 19:07","pubTimestamp":1779880037,"startTime":"0","endTime":"0","summary":"日本监管机构已授予万达生物制药旗下在研药物Imsidolimab孤儿药资格，用于治疗泛发性脓疱型银屑病。\n这一认定旨在鼓励针对罕见疾病的药物开发，可能为该药未来在日本市场的审批与商业化提供路径支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VNDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172511226","title":"万达生物制药宣布Nereus™（Tradipitant）在美国上市，系40余年来首款晕动症新药","url":"https://stock-news.laohu8.com/highlight/detail?id=1172511226","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172511226?lang=zh_cn&edition=full","pubTime":"2026-05-04 20:03","pubTimestamp":1777896224,"startTime":"0","endTime":"0","summary":"万达生物制药近日宣布，其研发的Nereus™（Tradipitant）已正式在美国市场投入商业销售。该药物成为四十多年来首款针对晕动症患者的新型药理治疗方案，标志着晕动症治疗领域迎来重大突破。\n此次上市意味着长期受晕动症困扰的患者将获得全新的治疗选择。Nereus™的推出不仅填补了该领域数十年的技术空白，更展现了医药创新对提升人类生活质量的持续推动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116493607","title":"万达生物制药：持有效处方患者可获Nereus药物 现金支付价为每剂85美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1116493607","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116493607?lang=zh_cn&edition=full","pubTime":"2026-05-02 04:38","pubTimestamp":1777667891,"startTime":"0","endTime":"0","summary":"万达生物制药宣布，持有合规处方的患者现可通过现金支付方式获取Nereus药物，单剂定价为85美元。该方案为患者提供了直接购买渠道，无需经过传统保险报销流程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140245743","title":"万达生物制药宣布Nereus™（Tradipitant）在美国上市，系四十余年来首款晕动症新药","url":"https://stock-news.laohu8.com/highlight/detail?id=1140245743","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1140245743?lang=zh_cn&edition=full","pubTime":"2026-05-02 04:37","pubTimestamp":1777667841,"startTime":"0","endTime":"0","summary":"美国医药市场迎来突破性进展——万达生物制药旗下新型晕动症治疗药物Nereus正式启动商业销售。这款神经激肽-1受体拮抗剂成为四十多年来首个针对晕动症的创新药理疗法，标志着该领域治疗空白终被填补。临床研究显示，口服Nereus能有效阻断引发恶心呕吐的关键神经信号通路。值得注意的是，该药物曾于2023年完成三期临床试验，数据显示用药组晕动症状发生率降低超70%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154480528","title":"万达生物制药敦促FDA撤回2027财年立法议程中延长药物审评时限的提案","url":"https://stock-news.laohu8.com/highlight/detail?id=1154480528","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154480528?lang=zh_cn&edition=full","pubTime":"2026-04-09 23:04","pubTimestamp":1775747053,"startTime":"0","endTime":"0","summary":"万达生物制药（Vanda Pharmaceuticals）近日呼吁美国食品药品监督管理局（FDA）从其2027财年立法议程中撤销一项旨在延长药物审评时间表的提案。该公司认为，此举可能对药物研发进程产生不利影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118743082","title":"万达生物制药启动Thetis研究：评估Nereus™预防GLP-1受体激动剂所致呕吐的临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1118743082","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118743082?lang=zh_cn&edition=full","pubTime":"2026-04-09 04:46","pubTimestamp":1775681177,"startTime":"0","endTime":"0","summary":"万达生物制药宣布正式启动名为\"Thetis研究\"的临床试验，该试验旨在评估其创新药物Nereus对GLP-1受体激动剂引发的呕吐症状的预防效果。这项研究将针对使用GLP-1受体激动剂治疗时出现胃肠道不良反应的患者群体，探索Nereus在控制药物相关性呕吐方面的潜在疗效。若试验结果积极，Nereus有望成为首款专门针对GLP-1类药物相关呕吐症状的预防性疗法，为全球数百万相关患者提供新的解决方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514852743","title":"Vanda Pharmaceuticals Inc.盘中异动 早盘急速上涨5.04%报4.69美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514852743","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514852743?lang=zh_cn&edition=full","pubTime":"2025-02-26 23:57","pubTimestamp":1740585475,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日23时57分，Vanda Pharmaceuticals Inc.股票出现异动，股价大幅拉升5.04%。截至发稿，该股报4.69美元/股，成交量36.1351万股，换手率0.62%，振幅2.58%。Vanda Pharmaceuticals Inc.股票所在的生物技术行业中，整体涨幅为0.08%。Vanda Pharmaceuticals Inc.公司简介：万达生物制药公司是一家生物制药公司，从事疗法的开发和商业化，以满足高度未满足的医疗需求并改善患者的生活。大部分收入来自 HETLIOZ 产品销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226235756a2550b7e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226235756a2550b7e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","VNDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512530179","title":"Vanda Pharmaceuticals Inc.2024财年实现净利润-18.90百万美元，同比减少852.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512530179","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512530179?lang=zh_cn&edition=full","pubTime":"2025-02-17 00:01","pubTimestamp":1739721682,"startTime":"0","endTime":"0","summary":"2月17日，Vanda Pharmaceuticals Inc.公布财报，公告显示公司2024财年净利润为-18.90百万美元，同比减少852.99%；其中营业收入为1.99亿美元，同比增加3.11%，每股基本收益为-0.33美元。从资产负债表来看，Vanda Pharmaceuticals Inc.总负债1.15亿美元，其中短期债务--，资产负债比为5.71，流动比率为0.05。机构评级：截至2025年2月17日，当前有3家机构对Vanda Pharmaceuticals Inc.目标价做出预测，其中目标均价为12.00美元，其中最低目标价为5.00美元，最高目标价为18.00美元。大部分收入来自 HETLIOZ 产品销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250217000154abd12279&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250217000154abd12279&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VNDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511699348","title":"Vanda Pharmaceuticals Inc.盘中异动 早盘急速下跌5.70%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511699348","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511699348?lang=zh_cn&edition=full","pubTime":"2025-02-14 22:31","pubTimestamp":1739543476,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日22时31分，Vanda Pharmaceuticals Inc.股票出现波动，股价急速下跌5.70%。Vanda Pharmaceuticals Inc.股票所在的生物技术行业中，整体涨幅为0.18%。Vanda Pharmaceuticals Inc.公司简介：万达生物制药公司是一家生物制药公司，从事疗法的开发和商业化，以满足高度未满足的医疗需求并改善患者的生活。大部分收入来自 HETLIOZ 产品销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214223116abcf0625&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214223116abcf0625&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","VNDA","BK4007","VRPX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132885459","title":"Vanda Pharmaceuticals Q4每股亏损$0.08，优于预期的每股亏损$0.11，销售额为$5319万，优于预期的$5225万","url":"https://stock-news.laohu8.com/highlight/detail?id=1132885459","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132885459?lang=zh_cn&edition=full","pubTime":"2025-02-14 05:04","pubTimestamp":1739480693,"startTime":"0","endTime":"0","summary":"Vanda Pharmaceuticals报告季度每股亏损$0.08，优于分析师预期的每股亏损$0.11，比预期高27.27%。这是较去年同期每股亏损$0.04增加100%的亏损。以上内容来自Benzinga Earnings专栏，原文如下：Vanda Pharma  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 27.27 percent. This is a 100 percent decrease over losses of $ per share from the same period last year.  The company reported quarterly sales of $53.19 million which beat the analyst consensus estimate of $52.25 million by 1.79 percent.  This is a 17.48 percent increase ov","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Vanda Pharmaceuticals Q4每股亏损$0.08，优于预期的每股亏损$0.11，销售额为$5319万，优于预期的$5225万","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VNDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510688898","title":"Vanda Pharmaceuticals Inc.盘中异动 急速下跌5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510688898","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510688898?lang=zh_cn&edition=full","pubTime":"2025-02-11 01:18","pubTimestamp":1739207899,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日01时18分，Vanda Pharmaceuticals Inc.股票出现波动，股价快速跳水5.00%。Vanda Pharmaceuticals Inc.股票所在的生物技术行业中，整体跌幅为0.14%。Vanda Pharmaceuticals Inc.公司简介：万达生物制药公司是一家生物制药公司，从事疗法的开发和商业化，以满足高度未满足的医疗需求并改善患者的生活。大部分收入来自 HETLIOZ 产品销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211011819a240c519&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211011819a240c519&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","VNDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2502705797","title":"Vanda Pharmaceuticals Inc.盘中异动 急速跳水5.11%报4.60美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2502705797","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2502705797?lang=zh_cn&edition=full","pubTime":"2025-01-09 01:47","pubTimestamp":1736358425,"startTime":"0","endTime":"0","summary":"北京时间2025年01月09日01时47分，Vanda Pharmaceuticals Inc.股票出现波动，股价快速下挫5.11%。截至发稿，该股报4.60美元/股，成交量30.5183万股，换手率0.52%，振幅5.69%。Vanda Pharmaceuticals Inc.股票所在的生物技术行业中，整体涨幅为0.27%。Vanda Pharmaceuticals Inc.公司简介：万达生物制药公司是一家生物制药公司，从事疗法的开发和商业化，以满足高度未满足的医疗需求并改善患者的生活。大部分收入来自 HETLIOZ 产品销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250109014706985f98ea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250109014706985f98ea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","VNDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2493716751","title":"HC Wainwright & Co.：重申Vanda Pharma评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2493716751","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2493716751?lang=zh_cn&edition=full","pubTime":"2024-12-23 20:15","pubTimestamp":1734956114,"startTime":"0","endTime":"0","summary":"HC Wainwright&Co.：重申Vanda Pharma评级，由买入调整至买入评级,目标价由18.00美元调整至18.00美元。万达生物制药公司简介：万达生物制药公司是一家生物制药公司，从事疗法的开发和商业化，以满足高度未满足的医疗需求并改善患者的生活。其商业产品组合包括三种产品，HETLIOZ用于治疗非24小时睡眠-觉醒障碍和Smith-Magenis综合征的夜间睡眠障碍；Fanapt用于治疗精神分裂症和PONVORY。其其他产品包括VHX-896、ASO Molecules、VQW-765、Tradipitant、VTR-297和VHX-896。大部分收入来自HETLIOZ产品销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241223202502a204c8ae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241223202502a204c8ae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VNDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2490704950","title":"Vanda Pharmaceuticals Inc.盘中异动 大幅下挫5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2490704950","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2490704950?lang=zh_cn&edition=full","pubTime":"2024-12-11 01:29","pubTimestamp":1733851771,"startTime":"0","endTime":"0","summary":"北京时间2024年12月11日01时29分，Vanda Pharmaceuticals Inc.股票出现异动，股价快速跳水5.08%。Vanda Pharmaceuticals Inc.股票所在的生物技术行业中，整体跌幅为1.11%。Vanda Pharmaceuticals Inc.公司简介：万达生物制药公司是一家生物制药公司，从事疗法的开发和商业化，以满足高度未满足的医疗需求并改善患者的生活。大部分收入来自 HETLIOZ 产品销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211012931984b14e6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211012931984b14e6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VNDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2486878043","title":"Vanda Pharmaceuticals Inc.盘中异动 大幅上涨5.02%报5.23美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2486878043","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2486878043?lang=zh_cn&edition=full","pubTime":"2024-11-27 22:53","pubTimestamp":1732719236,"startTime":"0","endTime":"0","summary":"北京时间2024年11月27日22时53分，Vanda Pharmaceuticals Inc.股票出现异动，股价大幅拉升5.02%。截至发稿，该股报5.23美元/股，成交量11.3383万股，换手率0.19%，振幅3.61%。Vanda Pharmaceuticals Inc.股票所在的生物技术行业中，整体涨幅为0.11%。Vanda Pharmaceuticals Inc.公司简介：万达生物制药公司是一家生物制药公司，从事疗法的开发和商业化，以满足高度未满足的医疗需求并改善患者的生活。大部分收入来自 HETLIOZ 产品销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127225357971a8e4a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127225357971a8e4a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","VNDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2483730989","title":"Vanda Pharmaceuticals Inc.2024财年第三财季实现净利润-5.32百万美元，同比减少3983.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483730989","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2483730989?lang=zh_cn&edition=full","pubTime":"2024-11-16 00:00","pubTimestamp":1731686420,"startTime":"0","endTime":"0","summary":"11月16日，Vanda Pharmaceuticals Inc.公布财报，公告显示公司2024财年第三财季净利润为-5.32百万美元，同比减少3983.21%；其中营业收入为47.65百万美元，同比增加22.75%，每股基本收益为-0.09美元。从资产负债表来看，Vanda Pharmaceuticals Inc.总负债1.04亿美元，其中短期债务2.45百万美元，资产负债比为6.21，流动比率为0.05。机构评级：截至2024年11月16日，当前有3家机构对Vanda Pharmaceuticals Inc.目标价做出预测，其中目标均价为12.17美元，其中最低目标价为5.50美元，最高目标价为18.00美元。大部分收入来自 HETLIOZ 产品销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000046abc513a5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000046abc513a5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VNDA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vandapharma.com","stockEarnings":[{"period":"1week","weight":-0.0832},{"period":"1month","weight":-0.1627},{"period":"3month","weight":-0.2544},{"period":"6month","weight":-0.3386},{"period":"1year","weight":-0.1027},{"period":"ytd","weight":-0.4751}],"compareEarnings":[{"period":"1week","weight":-0.0022},{"period":"1month","weight":0.0059},{"period":"3month","weight":0.0334},{"period":"6month","weight":0.1735},{"period":"1year","weight":0.1501},{"period":"ytd","weight":0.1286}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Vanda Pharmaceuticals Inc.于2002年在特拉华州注册成立。该公司是一家全球领先的生物制药公司，专注于创新疗法的开发和商业化，以解决高度未满足的医疗需求并改善患者的生活。该公司努力推进新的方法，通过负责任的创新将重要的新药推向市场。该公司致力于在药物发现、临床试验和产品的商业定位中使用支持健全科学的技术，包括遗传学和基因组学。","yearOnYearQuotes":[{"month":1,"riseRate":0.45,"avgChangeRate":-0.03173},{"month":2,"riseRate":0.5,"avgChangeRate":0.001567},{"month":3,"riseRate":0.4,"avgChangeRate":-0.029111},{"month":4,"riseRate":0.45,"avgChangeRate":-0.010662},{"month":5,"riseRate":0.45,"avgChangeRate":0.722524},{"month":6,"riseRate":0.571429,"avgChangeRate":0.043498},{"month":7,"riseRate":0.380952,"avgChangeRate":-0.039691},{"month":8,"riseRate":0.47619,"avgChangeRate":0.000391},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.049821},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.014281},{"month":11,"riseRate":0.65,"avgChangeRate":0.054208},{"month":12,"riseRate":0.55,"avgChangeRate":0.052442}],"exchange":"NASDAQ","name":"万达生物制药","nameEN":"Vanda Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"万达生物制药(VNDA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供万达生物制药(VNDA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"万达生物制药,VNDA,万达生物制药股票,万达生物制药股票老虎,万达生物制药股票老虎国际,万达生物制药行情,万达生物制药股票行情,万达生物制药股价,万达生物制药股市,万达生物制药股票价格,万达生物制药股票交易,万达生物制药股票购买,万达生物制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"万达生物制药(VNDA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供万达生物制药(VNDA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}